


Total U.S. 2020 Net Sales for Selected Drugs with FDA-Approval by Medicare Usage for Both Orphan & Non-Orphan Indications



Source: OIG analysis of 2018 Medicare Part B claims and Part D PDE records. PCMA research based on SSR Health analysis of Symphony Health Solutions.

Methodology: Drugs chosen from OIG report, top expenditure drugs in Medicare Part B and Part D with orphan and non-orphan use designations. Usage metrics are from OIG report Exhibit 6, net sales data is total U.S. net sales in 2020.

Notes: Opdivo and Keytruda both have FDA approval for orphan indications to treat small cell lung cancer (SCLC) as well as nonorphan indications to treat non-small cell lung cancers (NSCLC). OIG removed units related to any form of lung cancer from their analysis because ICD-10 diagnosis codes do not distinguish between SCLC and NSCLC. Of the 15 drugs included in the OIG report Exhibit 6, 12 are displayed here. Gammagard liquid was included in the OIG report, but is not included here because SSR Health does not have manufacturer disclosed U.S. net sales. Eylea and Orencea were not included because both are orphan drugs with FDA-Approval for ONLY non-orphan indications.